ArticleBlood2022
Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma.
Open access · bronzeAbstract readLetter
In one paragraph
Article in Blood, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 3 pooled it
3.3field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Examining the immunological responses to COVID-19 vaccination in multiple myeloma patients: a systematic review and meta-analysis.BMC geriatrics · 2024Pooled it
- Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis.Blood advances · 2022Pooled it
- Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis.Blood cancer journal · 2022Pooled it
- Pre-vaccine immune profiling in cancer patients identifies correlates of COVID-19 vaccine responses.Human vaccines & immunotherapeutics · 2025Article
- Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia.Blood advances · 2025Observational
- Immune responses after one versus two Influenza A/B vaccinations in patients with multiple myeloma.Annals of hematology · 2025Article
- Article
- Patients with multiple myeloma infected with COVID-19 during autologous stem cell transplantation.Infectious agents and cancer · 2024Article
- Breakthrough Infections in SARS-CoV-2-Vaccinated Multiple Myeloma Patients Improve Cross-Protection against Omicron Variants.Vaccines · 2024Article
- Cytokine-responsive T- and NK-cells portray SARS-CoV-2 vaccine-responders and infection in multiple myeloma patients.Leukemia · 2024Article
- Humoral and cellular responses to SARS-CoV-2 in patients with B-cell haematological malignancies improve with successive vaccination.British journal of haematology · 2023Article
- Review
- Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasia.Cancer medicine · 2023Article
- Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma.Frontiers in oncology · 2023Article
- Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma.Nature cancer · 2023Observational
- Persistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapidFrontiers in immunology · 2023Article
- Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma.Frontiers in oncology · 2023Article
- Immunogenicity of SARS-CoV-2 vaccines in patients with cancer.Trends in molecular medicine · 2022Review
- Article
- Antibody and T-cell responses by ultra-deep T-cell receptor immunosequencing after COVID-19 vaccination in patients with plasma cell dyscrasias.British journal of haematology · 2022Article
Corrections and comments
- Commented on by
Authors and funding
17 authors at 2 institutions in 1 country.
Julius C EnßleDepartment of Medicine, Hematology/Oncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Julia CampeFrankfurt Cancer Institute (FCI), Frankfurt am Main, Germany.ORCID 0000-0002-9290-9697
Amelie SchwengerFrankfurt Cancer Institute (FCI), Frankfurt am Main, Germany.
Eliza WiercinskaInstitute for Transfusion Medicine and Immunohematology, Goethe University, Frankfurt am Main, Germany.ORCID 0000-0002-8434-6492
Helen HellsternInstitute for Transfusion Medicine and Immunohematology, Goethe University, Frankfurt am Main, Germany.
Ralf DürrwaldRobert Koch-Institut, Berlin, Germany.ORCID 0000-0002-3432-0438
Michael A RiegerDepartment of Medicine, Hematology/Oncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.ORCID 0000-0002-4158-5872
Sebastian WolfDepartment of Medicine, Hematology/Oncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Olivier BalloDepartment of Medicine, Hematology/Oncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Björn SteffenDepartment of Medicine, Hematology/Oncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Hubert ServeDepartment of Medicine, Hematology/Oncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.ORCID 0000-0001-8472-5516
Halvard BonigInstitute for Transfusion Medicine and Immunohematology, Goethe University, Frankfurt am Main, Germany.ORCID 0000-0003-0088-2675
Holger F RabenauInsitute for Medical Virology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany; and.
Marek WideraInsitute for Medical Virology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany; and.ORCID 0000-0001-5417-9307
Sandra CiesekInsitute for Medical Virology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany; and.
Ivana von MetzlerDepartment of Medicine, Hematology/Oncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.ORCID 0000-0003-1699-4313
Evelyn UllrichFrankfurt Cancer Institute (FCI), Frankfurt am Main, Germany.ORCID 0000-0001-8530-1192
Goethe University Frankfurt · DERobert Koch Institute · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
BNT162 VaccineCOVID-19HumansImmunity, CellularMultiple MyelomaSARS-CoV-2T-LymphocytesBNT162 Vaccine
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.